Powell v. Commonwealth ( 2015 )


Menu:
  • PRESENT: Lemons, C.J., Goodwyn, Millette, Mims, McClanahan,
    and Powell, JJ., and Lacy, S.J.
    DERRICK RENARD POWELL
    OPINION BY
    v.   Record No. 132028                 CHIEF JUSTICE DONALD W. LEMONS
    January 8, 2015
    COMMONWEALTH OF VIRGINIA
    FROM THE COURT OF APPEALS OF VIRGINIA
    In this appeal, we consider whether the evidence was
    sufficient to sustain a conviction for distribution of an
    imitation Schedule I or II controlled substance where the
    substance actually distributed was a Schedule VI controlled
    substance.   We also consider whether the evidence was
    sufficient to establish that the substance was in a form such
    that it could be mistaken for a Schedule I or II controlled
    substance, and whether the defendant made any express or
    implied representations that the substance was a Schedule I or
    II controlled substance.
    I. Facts and Proceedings
    Derrick Renard Powell ("Powell") was tried by the Circuit
    Court of the City of Lynchburg ("trial court") upon an
    indictment charging distribution of an imitation Schedule I or
    II controlled substance, in violation of Code § 18.2-248.
    Powell was found guilty and sentenced to three years'
    imprisonment, with one year and ten months suspended.
    1
    At trial, Detective Daniel M. Bailey ("Bailey") testified
    that he was working undercover in Lynchburg on December 22,
    2011, when he drove through an area he described as "an open
    air drug market."   He observed Powell on the side of the road,
    and as Bailey drove by, Powell made a waving motion with his
    hand to get Bailey to pull over.     Bailey rolled down his window
    and when Powell walked up to him, Bailey asked him if "he was
    straight."   Bailey testified that phrase "is a common slang in
    the drug trade to see if he had any product on him.    Anything
    for sale."
    Bailey testified that Powell stated that "he had what I
    needed and asked what I wanted."     Bailey responded that he
    needed "a four," which is slang for 40 dollars worth of
    cocaine.   Taylor then went into his house, which was close by;
    and when he returned, he dropped a clear plastic baggie
    containing "a white rock[-like] substance" into Bailey's hand,
    and Bailey gave him 40 dollars in cash.    Bailey testified that
    he took the substance back to his office and thereafter mailed
    it to the lab.
    Bailey testified that the substance was a "[h]ard white
    rock[-like] substance," and that crack cocaine is also a hard,
    white, rock-like substance.    When Bailey was shown the
    substance in court, he testified that to his "naked eye" it
    looked like crack cocaine.    On cross-examination, Bailey
    2
    admitted that when he got back to the police station after the
    exchange and examined the substance, he realized that it was a
    white pill cut in half.    He also testified that it was packaged
    in a "knotted baggie."
    Kelly Howerter ("Howerter") is a forensic scientist with
    the Virginia Department of Forensic Science who analyzed the
    substance Powell sold to Bailey.     She testified that the
    substance was quetiapine, which is a Schedule VI controlled
    substance in Virginia.    See Code § 54.1-3455(2).   When the
    Commonwealth's Attorney asked what quetiapine was, Howerter
    testified it was out of her realm of experience, but that she
    believed it was some kind of "antibiotic type prescription
    pill." *   Howerter testified that the substance was white and
    solid, and was one half of an oblong shaped pill.     She
    testified that she had never seen crack cocaine in a pill form,
    but what she received looked like "a plastic bag corner that
    just had a white substance inside of it."     Howerter testified
    that she was unaware if quetiapine was ever mixed with cocaine.
    The Commonwealth rested, and Powell made a motion to
    strike.    He argued that he could not be convicted of
    *
    Quetiapine is actually a type of antipsychotic drug approved
    for the treatment of schizophrenia, bipolar disorder, and along
    with an antidepressant for treatment of major depressive
    disorder. See National Institutes of Health, Quetiapine,
    http://www.nlm.nih.gov/medlineplus/druginfo/meds/a698019.html
    (last visited Nov. 3, 2014).
    3
    distributing an imitation controlled substance because the
    substance was already a controlled substance, so he could only
    be a convicted of a misdemeanor for selling a Schedule VI drug.
    The trial court denied the motion to strike, reasoning that:
    [T]he gravamen of this offense is
    possession of a[n] imitation of a
    controlled substance and the intent to
    distribute that substance passing it off as
    a controlled substance and the focus is not
    on what the imitation consists of but
    rather what is being imitated with the
    controlled substance or the imitation
    controlled substance and what the intent of
    the defendant is trying to pass that
    substance off as.
    The defense rested and Powell renewed his motion.    Powell
    reiterated his previous argument that the substance at issue
    was already a controlled substance.   He also argued that he
    never said or indicated that he was selling Bailey cocaine, and
    he argued that the substance did not have the appearance of
    cocaine since it was just a white pill cut in half.   The trial
    court denied the motion to strike and found Powell guilty of
    the charge.
    Powell appealed his conviction to the Court of Appeals of
    Virginia.   The Court of Appeals issued a published opinion in
    which it affirmed Powell's conviction.    Powell v. Commonwealth,
    
    62 Va. App. 579
    , 
    750 S.E.2d 229
    (2013).   First, the Court of
    Appeals held that Powell's "representations regarding the
    substance, together with the packaging of the substance in a
    4
    plastic knotted baggie, made it likely that the substance would
    be mistaken for crack cocaine as required by Code § 18.2-247."
    
    Id. at 588,
    750 S.E.2d at 233.   Second, the Court of Appeals
    held that although the substance was a controlled substance,
    because it was a Schedule VI substance, such classification
    established that it was not subject to abuse.   
    Id. at 590,
    750
    S.E.2d at 234.   Accordingly, the Court of Appeals concluded
    that the trial court did not err in holding the evidence was
    sufficient to convict Powell of distributing an imitation
    controlled substance.   
    Id. at 591,
    750 S.E.2d at 234.
    Powell filed a petition for appeal in this Court, and we
    awarded him an appeal on the following assignments of error:
    1.   Under Section 18.2-247(B)(ii) of the Code of Virginia,
    1950, as amended, the trial court erred in finding that
    the evidence was sufficient to establish that the
    substance Appellant gave to Investigator Bailey was not a
    controlled substance subject to abuse, and, in affirming
    the trial court's decision, the Court of Appeals erred in
    both applying a statutory construction to Section 18.2-
    247(B)(ii) to link the phrase "subject to abuse" to the
    Drug Control Act (Section 54.1-3400 et seq.) and in its
    application of the statutory construction.
    2.   Under Section 18.2-247(B)(1) of the Code of Virginia,
    1950, as amended, the trial court erred in finding that
    the evidence was sufficient to establish that the
    substance was in a form such that it would be mistaken for
    cocaine, and the Court of Appeals erred in affirming the
    trial court's decision.
    3.   Under Section 18.2-247(B)(2) of the Code of Virginia,
    1950, as amended, the trial court erred in finding that
    the evidence was sufficient to establish that Appellant
    made any express or implied representations that the
    5
    substance was cocaine, and the Court of Appeals erred in
    affirming the trial court's decision.
    II.   Analysis
    A.   Standard of Review
    "When reviewing a defendant's challenge to the sufficiency
    of the evidence to sustain a conviction, this Court reviews the
    evidence in the light most favorable to the Commonwealth, as
    the prevailing party at trial, and considers all inferences
    fairly deducible from that evidence."         Allen v. Commonwealth,
    
    287 Va. 68
    , 72, 
    752 S.E.2d 856
    , 858-59 (2014) (internal
    quotation marks, alterations, and citation omitted).        "The
    lower court will be reversed only if that court's judgment is
    plainly wrong or without evidence to support it."        
    Id. at 72,
    752 S.E.2d at 859 (internal quotation marks omitted).        To the
    extent we must interpret a statute, that is a question of law
    that we review de novo.      See Woodard v. Commonwealth, 
    287 Va. 276
    , 280, 
    754 S.E.2d 309
    , 311 (2014).
    B.   Code § 18.2-247(B)(ii)
    Powell was convicted of violating Code § 18.2-248, which
    makes it a felony to distribute an imitation controlled
    substance.    The term "imitation controlled substance" is
    defined in Code § 18.2-247(B) to mean:
    (i) a counterfeit controlled substance or
    (ii) a pill, capsule, tablet, or substance
    of any form whatsoever which is not a
    controlled substance subject to abuse, and
    6
    1. Which by overall dosage unit appearance,
    including color, shape, size, marking and
    packaging or by representations made, would
    cause the likelihood that such a pill,
    capsule, tablet, or substance in any other
    form whatsoever will be mistaken for a
    controlled substance unless such substance
    was introduced into commerce prior to the
    initial introduction into commerce of the
    controlled substance which it is alleged to
    imitate; or
    2. Which by express or implied
    representations purports to act like a
    controlled substance as a stimulant or
    depressant of the central nervous system
    and which is not commonly used or
    recognized for use in that particular
    formulation for any purpose other than for
    such stimulant or depressant effect, unless
    marketed, promoted, or sold as permitted by
    the United States Food and Drug
    Administration.
    (Emphasis added.)   There was no allegation or evidence
    presented that Powell distributed a "counterfeit controlled
    substance."   In this case, the Commonwealth was required to
    prove that the substance Powell distributed was "a pill,
    capsule, tablet, or substance in any form whatsoever which is
    not a controlled substance subject to abuse." (Emphasis added.)
    On appeal, Powell does not dispute that he distributed a
    substance to Bailey.    There is also no dispute that the
    substance Powell distributed was quetiapine, a Schedule VI
    controlled substance.    The initial issue before this Court is
    limited to the question whether quetiapine, which is a Schedule
    7
    VI controlled substance, is "a controlled substance subject to
    abuse" within the intendment of Code § 18.2-247(B)(ii).
    Powell argues that quetiapine is a controlled substance
    subject to abuse, and that the Court should apply the plain
    meaning of those words instead of relying upon statutory
    construction to determine the meaning of the phrase "subject to
    abuse."   Powell argues that the Court of Appeals should not
    have looked to the "phraseology" of the Drug Control Act, Code
    § 54.1-3400, et seq., to interpret the meaning of the "subject
    to abuse" clause, and instead should have used the "plain,
    dictionary meaning" of that phrase.
    Powell relies on the Court of Appeals' decision in Rhodes
    v. Commonwealth, 
    12 Va. App. 473
    , 475, 
    404 S.E.2d 522
    , 523
    (1991), to support his argument that the phrase "subject to
    abuse" should be given its plain, dictionary meaning.   Powell
    is correct that in Rhodes, the Court of Appeals looked to
    Webster's Dictionary to determine the meaning of the phrase
    "subject to abuse," and held that the phrase meant "ha[ving] a
    disposition or tendency to be misused or is liable to being
    misused."   
    Id. However, in
    Rhodes, the Court of Appeals was
    interpreting a former version of Code § 18.2-247 that was
    worded differently than it is today.
    8
    In 1991, Code § 18.2-247(B) stated that:
    The term "imitation controlled substance"
    when used in this article means a pill,
    capsule, tablet, or substance in any form
    which is not a controlled substance, which
    is subject to abuse.
    (1988 Repl. Vol.)(emphasis added).     Under this section, as it
    existed in 1991, in order to prove that a defendant had
    distributed an imitation controlled substance, the Commonwealth
    first had to prove that the substance distributed was not a
    controlled substance, and second, that the substance was itself
    subject to abuse.    
    Rhodes, 12 Va. App. at 474-75
    , 404 S.E.2d at
    523.    Because the substance involved in Rhodes could not, by
    statute, be a controlled substance, there was no reason for the
    Court of Appeals to refer to the Drug Control Act for any
    further assistance in defining the phrase "subject to abuse."
    The phrase "subject to abuse" did not refer to a controlled
    substance; rather, it referred to an imitation substance which
    was not a controlled substance, and therefore the Court of
    Appeals properly applied the plain meaning of the phrase
    instead of looking to the Drug Control Act.
    The General Assembly, however, amended Code § 18.2-247 in
    1992.    Code § 18.2-247(B), as amended in 1992, stated:
    The term "imitation controlled substance"
    when used in this article means a pill,
    capsule, tablet, or substance in any form
    whatsoever which is not a controlled
    substance subject to abuse.
    9
    (Cum. Supp. 1992)(emphasis added).   See also 1992 Acts ch. 756.
    Not long after this amendment was made, the Court of Appeals
    had another opportunity to interpret Code § 18.2-247(B) in
    Werres v. Commonwealth, 
    19 Va. App. 744
    , 
    454 S.E.2d 36
    (1995).
    In Werres, the Court of Appeals correctly pointed out:
    The 1992 Amendment to Code § 18.2-247(B)
    removed the comma and the words "which is"
    preceding the words "subject to abuse."
    This amendment effectively deleted the
    entire subordinate clause. By deleting the
    comma and the subordinate clause, the
    legislature significantly changed not only
    the sentence's structure, but also its
    meaning. The legislature thereby
    substantively changed the definition of the
    statutory offense.
    
    Id. at 747,
    454 S.E.2d at 38.   The Court of Appeals held that
    under the revised definition of an imitation controlled
    substance, the Commonwealth was now required to prove that the
    substance was "not a controlled substance subject to abuse."
    
    Id. at 748,
    454 S.E.2d at 38.
    This portion of Code § 18.2-247(B) has remained unchanged
    since 1992.   Under Code § 18.2-247(B) as it currently exists,
    the phrase "subject to abuse" refers to a controlled substance.
    Therefore, we must determine whether the substance at issue,
    quetiapine, is a "controlled substance subject to abuse."    Code
    § 18.2-247(A) states explicitly that "[w]herever the terms
    'controlled substances' and 'Schedules I, II, III, IV, V and
    10
    VI' are used in Title 18.2, such terms refer to those terms as
    they are used or defined in the Drug Control Act (§ 54.1-3400
    et seq.)."   Accordingly, we are required to look to the Drug
    Control Act in order to determine the meaning of a "controlled
    substance subject to abuse."
    The Board of Pharmacy is charged with administering
    Article 5 of the Drug Control Act and adding or removing
    substances from the various schedules.    Code § 54.1-3443(A).
    Code § 54.1-3443(A) lists the various factors that should be
    considered when determining on which schedule to place a
    particular substance.   One of those factors is "the actual or
    relative potential for abuse."    Code § 54.1-3443(A)(1).   Any
    substance which the Board determines has a potential for abuse
    is required to be controlled.    Code § 54.1-3443(B).   Schedules
    I-V controlled substances all include a potential for abuse,
    with Schedule I substances having the highest potential for
    abuse, and Schedule V substances the lowest.    See Code §§ 54.1-
    3445 through 54.1-3454.   There is no mention, however, of the
    potential for abuse in factors for inclusion in Schedule VI.
    See Code § 54.1-3455(1)-(3)(defining the covered classes of
    drugs or devices to be controlled by Schedule VI by reference
    to stimulant or depressant content, toxicity, safety, need for
    supervision by a licensed practitioner, and labeling
    requirements).
    11
    By excluding the factor of "potential for abuse" in
    Schedule VI, but including it in Schedules I-V, the General
    Assembly has indicated to the Board that any substance with a
    potential for abuse should be included on Schedule I-V, and not
    on Schedule VI.   Any controlled substances the Board lists on
    Schedule VI are therefore not characterized by a potential for
    abuse.   Rightly or wrongly, after considering the numerous
    factors set out in Article 5 for placement on the various
    Schedules, the Board determined that quetiapine did not have a
    potential for abuse and listed it on Schedule VI instead of any
    of the other Schedules that included a potential for abuse.
    Powell distributed the quetiapine, which is a controlled
    substance, to Bailey.     However, because it is a Schedule VI
    controlled substance it is not a controlled substance subject
    to abuse as defined by the Drug Control Act.       Accordingly, the
    Commonwealth met its burden of proving that the substance
    Powell distributed was "a pill, capsule, tablet, or substance
    in any form whatsoever which is not a controlled substance
    subject to abuse."   Code § 18.2-247(B)(ii).
    C.    Code § 18.2-247(B)(1)
    Powell's second assignment of error challenges the
    sufficiency of the evidence to establish that the substance was
    in a form such that it would be mistaken for cocaine.      Code §
    18.2-247(B)(1).   Powell argues that the half-tablet of
    12
    quetiapine was not so similar in appearance that it would be
    mistaken for cocaine.      However, the Commonwealth's evidence
    proved that the substance was a hard, white substance and was
    packaged in a knotted plastic baggie.
    Detective Bailey testified that crack cocaine is "a hard
    form of powder cocaine."     He was shown the substance that
    Powell sold him in court, in the same packaging he received
    from Powell, and was asked what it looked like to his "naked
    eye."    Bailey responded, "[c]rack cocaine."      This evidence,
    which we view in the light most favorable to the Commonwealth
    on appeal, was sufficient to permit the trier of fact to find
    beyond a reasonable doubt that the Commonwealth established
    that the substance, by appearance and packaging, would likely
    be mistaken for crack cocaine.
    D.   Code § 18.2-247(B)(2)
    In his third assignment of error, Powell argues that the
    evidence was insufficient to establish that he made any express
    or implied representations that the substance was cocaine.          He
    argues there was no evidence he made any express
    representations that the substance was cocaine.       He also argues
    there was no evidence of any such implied representation
    either, as the Commonwealth did not prove that Powell
    understood what Bailey wanted when he asked for a "four."
    13
    The Commonwealth's evidence proved that Bailey was driving
    through an "open air drug market" when Powell waved him down.
    Bailey asked if he was "straight," which is common slang in the
    drug trade to ask whether a person has any "product" for sale.
    Powell responded that he had what Bailey needed.     Bailey told
    Powell that needed a "four."      Detective Bailey testified that a
    "four" is a common term used in the drug trade to mean 40
    dollars worth of cocaine.    At that point, Powell did not ask
    what a "four" was or indicate in any way that he did not
    understand what Bailey was requesting.     Instead, he agreed to
    deal with Bailey, and went inside his house to retrieve the
    substance.   Minutes later, Powell came back to the car and
    dropped a white, rock-like substance into Bailey's hand in
    exchange for 40 dollars.    This evidence, viewed in the light
    most favorable to the Commonwealth, demonstrates that Powell
    implied that the substance he was selling Bailey was 40 dollars
    worth of cocaine.
    III.   Conclusion
    We will affirm the judgment of the Court of Appeals
    holding that the evidence was sufficient to establish that
    Powell distributed an imitation controlled substance in
    violation of Code § 18.2-248(A).
    Affirmed.
    14
    JUSTICE MILLETTE, with whom JUSTICE GOODWYN and SENIOR JUSTICE
    LACY join, dissenting.
    I respectfully dissent.   The majority opinion errs in
    holding that Schedule VI includes only substances that are not
    subject to abuse on the basis that Schedule VI does not contain
    the explicit "potential for abuse" requirement found in
    Schedules I through V.    This analysis ignores the requirements
    of Schedule VI on their own and within the greater statutory
    context, which shows that substances that are subject to abuse
    may, and sometimes must, be categorized under Schedule VI.
    Schedule VI includes:
    Every drug, not included in Schedules [I through V],
    which because of its toxicity or other potentiality
    for harmful effect, or the method of its use, or the
    collateral measures necessary to its use, is not
    generally recognized among experts . . . as safe for
    use except by or under the supervision of a
    practitioner."
    Code § 54.1-3455(2) (emphasis added).    An unsafe method of
    using a drug includes "actual or relative potential for abuse."
    Code § 54.1-3443(A)(1).   The Board of Pharmacy may thus
    categorize under Schedule VI a substance that is subject to
    abuse, even if such potential abuse does not rise to the level
    as set forth in Schedules I through V.   Code § 54.1-3455(2).
    Also, some substances with a potential for abuse must be
    categorized under Schedule VI.   The majority opinion overlooks
    15
    that Schedules I through V contain requirements in addition to
    a "potential for abuse" that must be independently satisfied in
    order to be categorized under those Schedules.    See Virginia
    Marine Res. Comm'n v. Chincoteague Inn, 
    287 Va. 371
    , 385, 
    757 S.E.2d 1
    , 8 (2014) (courts avoid reading statutory language as
    surplusage).    In particular, Schedule I requires a substance to
    have "no accepted medical use in treatment in the United States
    or lack[] accepted safety for use in treatment under medical
    supervision."   Code § 54.1-3445(2).   Schedules II through V
    require a substance to have a "currently accepted medical use
    in treatment in the United States."    Code §§ 54.1-3447(2);
    54.1-3449(2); 54.1-3451(2); 54.1-3453(2).    And Schedules II
    through V all require that the substance, when abused, lead to
    some degree of physical or psychological dependence.     Code
    §§ 54.1-3447(3); 54.1-3449(3); 54.1-3451(3); 54.1-3453(3).
    A substance can have a potential for abuse but fail to
    possess one of these additional requirements for categorization
    under Schedules I through V.    Yet the Board of Pharmacy must
    still include such a substance in one of the Schedules because
    of its potential for abuse.    Code § 54.1-3443(B).   Such a
    substance can only be categorized under Schedule VI.     Code
    § 54.1-3455(2).
    Thus, Schedule VI encompasses both substances that are and
    are not subject to the abuse.    The only evidence the
    16
    Commonwealth introduced at trial to prove that Quetiapine is
    "not a controlled substance subject to abuse" is that
    Quetiapine is a Schedule VI controlled substance.   Because this
    evidence is insufficient as a matter of law to prove that
    Quetiapine is not subject to abuse, the evidence was
    insufficient to sustain Powell's conviction of distributing an
    imitation controlled substance.    Code §§ 18.2-247(B)(ii); 18.2-
    248.   I would therefore reverse the judgment of the Court of
    Appeals and vacate Powell's conviction.
    17
    

Document Info

Docket Number: 132028

Filed Date: 1/8/2015

Precedential Status: Precedential

Modified Date: 1/8/2015